Literature DB >> 2581709

Recombinant interleukin 2 rapidly augments human natural killer cell activity.

D Kabelitz, H Kirchner, D Armerding, H Wagner.   

Abstract

Recombinant human interleukin 2 (r-IL-2) rapidly stimulated human natural killer cell activity in vitro. Augmentation of NK activity occurred within 1 hr of preincubation with r-IL-2. Responsive killer cells were typical NK cells as shown by cell fractionation procedures. These included Percoll density gradient separation and depletion of OKT3+ T cells by an indirect rosetting method. Analysis with a panel of polyclonal and monoclonal antibodies against alpha and gamma interferon revealed that this early enhancement of NK activity by r-IL-2 was independent of the production of both types of interferon.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2581709     DOI： 10.1016/0008-8749(85)90386-7

Source DB:  PubMed          Journal:  Cell Immunol        ISSN： 0008-8749            Impact factor:   4.868


  11 in total

1.  Interleukin-2 can induce suppression of human natural killer cell cytotoxicity.

Authors:  K Hellstrand; S Hermodsson
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

2.  Effect of interleukin-2 on the ex vivo growth of human myeloma cells.

Authors:  D Peest; I de Vries; R Hölscher; R Leo; H Deicher
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Suppressor cells induced by influenza virus inhibit interleukin-2 production in mice.

Authors:  V Del Gobbo; N Villani; S Marini; E Balestra; R Caliò
Journal:  Immunology       Date:  1990-03       Impact factor: 7.397

4.  Interleukin-2-induced lymphoproliferative responses.

Authors:  A Winkelstein; L D Weaver; N Salva; L L Machen
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Immunomodulation by indoleamines: serotonin and melatonin action on DNA and interferon-gamma synthesis by human peripheral blood mononuclear cells.

Authors:  E S Arzt; S Fernández-Castelo; L M Finocchiaro; M E Criscuolo; A Díaz; S Finkielman; V E Nahmod
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

6.  Role of interleukin-2 and interferon-gamma in induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432.

Authors:  H Yamaue; H Tanimura; M Iwahashi; M Tani; T Tsunoda; K Tabuse; K Kuribayashi; K Saito
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  A strategy for evaluating lymphokine activation and novel monoclonal antibodies in antibody-dependent cell-mediated cytotoxicity and effector cell retargeting assays.

Authors:  R P Junghans
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  The regulation of natural killer cell activity by splenic nonspecific suppressor cells and its modification in cancer patients.

Authors:  E Yanagawa; T Toge; A Sawamura; Y Kegoya; N Baba; T Hattori
Journal:  Jpn J Surg       Date:  1988-11

Review 9.  "Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy.

Authors:  Senthamil R Selvan; John P Dowling
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

Review 10.  Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review.

Authors:  Sandeep Nayar; Prokar Dasgupta; Christine Galustian
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.